AI-generated analysis. Always verify with the original filing.
On February 18, 2026, Theriva Biologics, Inc. entered into a License Agreement with Rasayana Therapeutics, constituting a material definitive agreement. The agreement is furnished as Exhibit 10.1, with a related press release as Exhibit 99.1 under Item 7.01.
Event Type
Disclosure
Mandatory
Variant
8-K
. Entry into a Material Definitive Agreement. On February 18, 2026 (the “Effective Date”), Theriva Biologics, Inc. (the “Company”) entered into a license agreem
and in the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Secur
. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 10.1* License Agreement between Theriva Biologics, Inc. and Rasayana Therapeutics,
Material Agreement